Literature DB >> 19912148

Continuous intrathecal baclofen therapy in children with cerebral palsy - when does improvement emerge?

K Ramstad1, R Jahnsen, B Lofterod, O H Skjeldal.   

Abstract

AIM: The aim of the study was to explore the timing of effects of intrathecal baclofen therapy in children with cerebral palsy.
METHODS: Thirty five children with severe disabilities with cerebral palsy who started continuous intrathecal baclofen therapy (CITB) were followed for 18 months. Pain, number of awakenings during night, spasticity, GMFM-66 scores and PEDI scores were recorded the day before pump implantation and after 6 and 18 months of treatment respectively.
RESULTS: Introduction of CITB was associated with changes across all ICF dimensions. Reduced pain and improved sleep occurred within 6 months of treatment. Social function improved within 6 months and continued to improve until 18 months of CITB. Mobility also improved, but with a latency.
CONCLUSION: There seems to be a sequence of changes after introduction of continuous intrathecal baclofen in a child with cerebral palsy that may guide the multidisciplinary team in their timing of therapy during post-surgical follow-up.
© 2009 The Author(s)/Journal Compilation © 2009 Foundation Acta Paediatrica.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19912148     DOI: 10.1111/j.1651-2227.2009.01596.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  10 in total

1.  Understanding the reasons for delayed referral for intrathecal baclofen therapy in pediatric patients with severe spasticity.

Authors:  Casey Melissa Berman; Melissa Ann Eppinger; Catherine Anne Mazzola
Journal:  Childs Nerv Syst       Date:  2014-11-16       Impact factor: 1.475

2.  Intrathecal baclofen therapy for spasticity of cerebral origin--does the position of the intrathecal catheter matter?

Authors:  Gnanamurthy Sivakumar; Yoong Yap; Mekidm Tsegaye; Michael Vloeberghs
Journal:  Childs Nerv Syst       Date:  2010-03-20       Impact factor: 1.475

3.  Cervical catheter placement for intrathecal baclofen test dose: is it safe?

Authors:  Samiul Muquit; Ismail Ughratdar; Harshal Ingale; Michael Vloeberghs
Journal:  Childs Nerv Syst       Date:  2012-02-12       Impact factor: 1.475

4.  Intrathecal baclofen therapy in severe head injury, first time in Nepal, a technique suitable for underdeveloped countries.

Authors:  Prabin Shrestha; Hridayesh Malla; Basant Pant; Takaomi Taira
Journal:  Asian J Neurosurg       Date:  2011-01

5.  Intrathecal baclofen therapy in paediatrics: a study protocol for an Australian multicentre, 10-year prospective audit.

Authors:  Kirsty Stewart; Gavin Hutana; Megan Kentish
Journal:  BMJ Open       Date:  2017-06-21       Impact factor: 2.692

Review 6.  Sleep Disorders in Childhood Neurological Diseases.

Authors:  Abdullah Tolaymat; Zhao Liu
Journal:  Children (Basel)       Date:  2017-09-22

7.  Musculoskeletal Pain Outcomes Pre- and Post Intrathecal Baclofen Pump Implant in Children With Cerebral Palsy: A Prospective Cohort Study.

Authors:  Chantel C Barney; Alyssa M Merbler; Jean Stansbury; Linda E Krach; Michael Partington; Patrick Graupman; Peter D Kim; Debbie Song; Frank J Symons
Journal:  Arch Rehabil Res Clin Transl       Date:  2020-03-09

8.  Pain in young people aged 13 to 17 years with cerebral palsy: cross-sectional, multicentre European study.

Authors:  Kathryn N Parkinson; Heather O Dickinson; Catherine Arnaud; Alan Lyons; Allan Colver
Journal:  Arch Dis Child       Date:  2013-04-20       Impact factor: 3.791

Review 9.  Intrathecal baclofen for treating spasticity in children with cerebral palsy.

Authors:  Monika J Hasnat; James E Rice
Journal:  Cochrane Database Syst Rev       Date:  2015-11-13

10.  European expert consensus on improving patient selection for the management of disabling spasticity with intrathecal baclofen and/or botulinum toxin type A.

Authors:  Bo Biering-Soerensen; Valerie Stevenson; Djamel Bensmail; Klemen Grabljevec; Mercedes Martínez Moreno; Elke Pucks-Faes; Joerg Wissel; Mauro Zampolini
Journal:  J Rehabil Med       Date:  2022-01-03       Impact factor: 2.912

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.